You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What information is available regarding alcohol use with Mounjaro® (tirzepatide)?
Eli Lilly and Company has not evaluated tirzepatide for alcohol use disorder or with concomitant alcohol use.
See important safety information, including boxed warning, in the attached prescribing information for MOUNJARO® (tirzepatide).
Alcohol use
Eli Lilly and Company cannot provide a recommendation on whether to use tirzepatide in a patient with concomitant alcohol use or comorbid alcohol use disorder (AUD). The healthcare practitioner may use the information provided, the patient’s prior medical history and concomitant medications, and other individual factors in developing a treatment plan. The healthcare practitioner should consider potential risks and benefits of treatment options and monitor appropriately.
Lilly cannot provide any information on tirzepatide and concomitant alcoholic beverage use because this has not been studied by Lilly.
In tirzepatide clinical trials conducted by Lilly, patients were excluded if they had a history of alcohol abuse or any condition that, in the opinion of the investigator, may preclude the patient from following and completing the protocol.1-5
Tirzepatide KwikPen contain benzyl alcohol as a preservative in the drug product solution.6 The addition of preservatives to the product formulation ensures that the drug solution maintains an antimicrobial environment (ie, slows the growth of bacteria) through the end of the product’s in-use period.7
Benzyl alcohol is included only in the multidose formulation of tirzepatide, including the multi-dose pen/KwikPen and the multi-dose vial.6 Benzyl alcohol is used as an excipient in a range of medicinal products that are administered intramuscularly, intravenously, and topically. Benzyl alcohol does not contain or metabolize to ethanol.7 Eli Lilly and Company has no clinical study data on use in people with AUD or the risk of metabolic acidosis associated with benzyl alcohol contained in the tirzepatide multi-dose formulations.
Tirzepatide is not indicated for treatment of AUD.
Although some independent, non-Lilly, studies on the use of tirzepatide in AUD exist, Lilly
- has not sponsored or reviewed these studies
- is not affiliated with these studies
- cannot confirm their scientific merit, clinical relevance, or generalizability, and
- has no plans to study tirzepatide for AUD.
Enclosed Prescribing Information
MOUNJARO® (tirzepatide) Injection, for subcutaneous use, Lilly
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
- Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. https://doi.org/10.1016/S0140-6736%2821%2901324-6
- Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. https://doi.org/10.1056/NEJMoa2107519
- Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583-598. https://doi.org/10.1016/S0140-6736(21)01443-4
- Del Prato S, Kahn SE, Pavo I, et al; SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811-1824. https://doi.org/10.1016/S0140-6736(21)02188-7
- Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534-545. https://doi.org/10.1001/jama.2022.0078
- MOUNJARO [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
- Nair B. Final report on the safety assessment of benzyl alcohol, benzoic acid, and sodium benzoate. Int J Toxicol. 2001;20(Suppl 3):23-50. https://www.doi.org/10.1080/10915810152630729.
Date of Last Review: July 22, 2026